Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia
Section snippets
Subjects and controls
Frozen samples of the cingulate cortex were available from 18 schizophrenic patients (seven males and 11 females) and 24 controls (19 males and five females). The mean age of schizophrenic patients (49.4 years, S.D. 15.7) did not differ from controls (47.3 years, S.D. 19.1), nor did mean post mortem interval (schizophrenia 14.9 h, S.D. 9.6; controls 18.0 h, S.D. 11.5). Toxicology reports were available for 16 schizophrenic patients, antipsychotic drugs were detected in seven and an additional case
Antigen characterization
The results of previous preliminary characterization studies indicated that members of the SP series of monoclonal antibodies detected synaptophysin, SNAP-25 and syntaxin. As shown in Fig. 1A, SP15 and SP17 both recognized 40 000 mol. wt proteins in CHO cells expressing synaptophysin, but not in the untransformed parent CHO cell line. Virtually identical results were obtained with the SY38 anti-synaptophysin antibody. The mobility of the synaptophysin band in CHO cells was reduced (40 000)
Discussion
The present results confirmed the reactivity of members of a panel of monoclonal antibodies with the presynaptic terminal proteins synaptophysin, SNAP-25 and syntaxin. Syntaxin immunoreactivity in the cingulate cortex in schizophrenia was increased, and the distribution of syntaxin in human cingulate cortex was much wider than that of synaptophysin. The ratio of N-CAM to synaptophysin immunoreactivity was studied as a possible marker of synaptic maturity. This ratio was significantly increased
Conclusions
Syntaxin immunoreactivity in the cingulate cortex from schizophrenics is increased, along with N-CAM and the N-CAM to synaptophysin ratio. These data are consistent with reported increases in glutamatergic afferents to the cingulate cortex in schizophrenia, and suggest the hypothesis that there may be functional impairments in neurotransmission in this region as well. Combined investigation of multiple synaptic proteins in other brain regions in schizophrenia may also be of value. In future
Acknowledgements
This work was supported by the Medical Research Council of Canada (W.G.H. and W.S.T.), the Stanley Foundation and NARSAD (W.G.H.), and the Alzheimer's Association of Ontario (W.S.T.). The authors thank Dr R. H. Scheller for pGEX–syntaxin constructs and Dr M. C. Wilson for SNAP-25. Dr B. A. Cunningham provided the antibody to N-CAM. The support and encouragement of Drs P. Davies, J. E. Kleinman, M. F. Casanova, J. Stevens, Mr M. Zito and Ms J. Gleeson is appreciated.
References (83)
Symptoms, signs, and diagnosis of schizophrenia
Lancet
(1995)- et al.
Human cDNA clones encoding two different isoforms of the nerve terminal protein SNAP-25
Gene
(1994) - et al.
Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics
Biol. Psychiat.
(1993) - et al.
Members of the VAMP family of synaptic vesicle proteins are components of glucose transporter-containing vesicles from rat adipocytes
J. biol. Chem.
(1992) - et al.
Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia
Neuroscience
(1995) - et al.
Synaptophysin gene expression in human brain: a quantitative in situ hybridization and immunocytochemical study
Neuroscience
(1994) - et al.
Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography
Neuroscience
(1995) A neural plasticity hypothesis of schizophrenia
Neurosci. Biobehav. Rev.
(1984)- et al.
Regional synaptic pathology in Alzheimer's disease
Neurobiol. Aging
(1992) - et al.
Human synaptic proteins with a heterogeneous distribution in cerebellum and visual cortex
Brain Res.
(1993)